The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months f ...

Now, with the cloning of its receptor and the generation of OX2 −/− mice, a possible role as an inhibitor for myeloid activation has emerged. The authors imply that CD200, acting through ...